Published in PLoS Pathog on February 06, 2015
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. Viruses (2015) 0.87
Retargeting FX-binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop. J Gen Virol (2016) 0.75
Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. Sci Rep (2015) 0.75
The relevance of coagulation factor X protection of adenoviruses in human sera. Gene Ther (2016) 0.75
Evaluation of D-dimer and lactate dehydrogenase plasma levels in patients with relapsed acute leukemia. Oncol Lett (2016) 0.75
Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 14.41
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 13.21
Adenovirus serotype 5 hexon mediates liver gene transfer. Cell (2008) 5.00
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature (2006) 4.59
Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol (2007) 4.54
Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol (2003) 4.48
Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus. J Cell Biol (1999) 4.00
Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A (2008) 3.00
The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol (1997) 2.84
Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol (2005) 2.84
Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood (2006) 2.67
Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood (2009) 2.55
Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity (2009) 2.44
The role of the nuclear pore complex in adenovirus DNA entry. EMBO J (1997) 2.37
Adenoviruses in immunocompromised hosts. Clin Microbiol Rev (2008) 2.20
Coagulation factor X activates innate immunity to human species C adenovirus. Science (2012) 2.09
Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood (2003) 2.06
First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis (2012) 1.87
Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther (2008) 1.66
Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol (2010) 1.58
Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood (2009) 1.51
Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther (2004) 1.50
Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach. J Control Release (2013) 1.48
Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther (2006) 1.47
Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med (2013) 1.45
Prediction of severe disseminated adenovirus infection by serum PCR. Lancet (2001) 1.44
Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis (1998) 1.40
The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog (2009) 1.37
The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer (2002) 1.29
Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis (2001) 1.29
Molecular evolution of human adenoviruses. Sci Rep (2013) 1.29
Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood (2010) 1.25
Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol (2007) 1.20
Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog (2010) 1.19
Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood (2007) 1.19
Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo. J Virol (2009) 1.18
Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol (2012) 1.14
Neonatal adenovirus infection: four patients and review of the literature. Pediatrics (1991) 1.12
Interactions between human plasma components and a xenogenic adenovirus vector: reduced immunogenicity during gene transfer. Mol Ther (2007) 1.10
Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. J Virol (2011) 1.09
Severe adenovirus infection in children. J Microbiol Immunol Infect (2003) 1.08
Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J Virol (2008) 1.02
Natural IgM antibodies: the orphaned molecules in immune surveillance. Adv Drug Deliv Rev (2006) 1.01
Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J Virol (2005) 1.00
IgM and its receptors: structural and functional aspects. Biochemistry (Mosc) (2011) 1.00
A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes. J Virol (2011) 0.96
Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Mol Ther (2009) 0.95
New insights into the molecular mechanisms of classical complement activation. Mol Immunol (2010) 0.94
Fulminant adenovirus hepatitis following unrelated bone marrow transplantation: failure of intravenous ribavirin therapy. Bone Marrow Transplant (1999) 0.92
Antiviral therapy for adenovirus infections. Antiviral Res (2006) 0.90
Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep (2013) 0.89
Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus). Gene Ther (2011) 0.86
A syndrome of transient encephalopathy associated with adenovirus infection. Pediatrics (2001) 0.86
Multispecificity of immunoglobulin M antibodies raised against advanced glycation end products: involvement of electronegative potential of antigens. J Biol Chem (2013) 0.84
Natural antibodies as a sensor of electronegative damage-associated molecular patterns (DAMPs). Free Radic Biol Med (2014) 0.82
Fulminant hepatic necrosis caused by adenovirus type 5 following bone marrow transplantation. Bone Marrow Transplant (1990) 0.81
Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bone Marrow Transplant (1996) 0.80
Coagulation factor binding orientation and dimerization may influence infectivity of adenovirus-coagulation factor complexes. J Virol (2013) 0.79
Vector systems for prenatal gene therapy: principles of adenovirus design and production. Methods Mol Biol (2012) 0.78